Evidence map›Paper›PMID 39869032›Full record

ReviewACS nano2025

Natural and Bioengineered Extracellular Vesicles in Diagnosis, Monitoring and Treatment of Cancer.

Xin Luo, Kathleen M McAndrews, Raghu Kalluri

Abstract readReview
In one paragraph

Review in ACS nano, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Article
  2. Green nanomedicine for cancer therapy.Chinese medical journal · 2026
    Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Frontiers in bacterial outer membrane vesicles: From basic characteristics to cancer therapy.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2026
    Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Xin LuoDepartment of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, Texas 77054, United States.
Kathleen M McAndrewsDepartment of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, Texas 77054, United States.ORCID 0000-0002-4092-4991
Raghu KalluriDepartment of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, Texas 77054, United States.ORCID 0000-0002-2190-547X

Funding

Biology and Function of Exosomes in CancerR35CA263815 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI RAGHU KALLURI · 2022 to 2026
$4.4M
Rigorous and reproducible mutational analysis of the urinary exosomal DNAR01CA231465 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DINNEY, COLIN P.N., KALLURI, RAGHU · 2019 to 2023
$3.1M
NCI NIH HHS R01 CA231465NCI NIH HHS R35 CA263815
6 · The paper itself

Abstract

Extracellular vesicles (EVs) are cell derived nanovesicles which are implicated in both physiological and pathological intercellular communication, including the initiation, progression, and metastasis of cancer. The exchange of biomolecules between stromal cells and cancer cells via EVs can provide a window to monitor cancer development in real time for better diagnostic and interventional strategies. In addition, the process of secretion and internalization of EVs by stromal and cancer cells in the tumor microenvironment (TME) can be exploited for delivering therapeutics. EVs have the potential to provide a targeted, biocompatible, and efficient delivery platform for the treatment of cancer and other diseases. Natural as well as engineered EVs as nanomedicine have immense potential for disease intervention. Here, we provide an overview of current knowledge of EVs' function in cancer progression, diagnostic and therapeutic applications for EVs in the cancer setting, as well as current EV engineering strategies.

Indexed as

BioengineeringExtracellular VesiclesNeoplasmsAnimalsHumansNanomedicineTumor Microenvironmentcancercancer immunotherapycargo loading methodsdiagnosisdrug deliveryExtracellular vesicles (EVs)immune microenvironmentlarge scale productionmonitoringtumor microenvironment (TME)

Identifiers

PMID39869032
PMCPMC12002402

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.